OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025 NANTES, France, September…
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies…
OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN:…
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025 NANTES, France, June 11, 6:30 PM – OSE Immunotherapeutics…